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Human papillomavirus is the causal factor for cervical cancer. However, the role of HPV infection in ovarian cancer is unclear. This
study aimed to determine the presence of human papillomavirus-16 (HPV-16) in ovarian cancer tissues. Archived human ovarian
cancer tissues (N¼54 cases, 50 are epithelial cancer, four are nonepithelial cancer) embedded in paraffin blocks were used. Controls
are 30 nonmalignant ovarian tissue blocks. In situ hybridisation (ISH) and immunohistochemistry (IHC) were used to detect the
presence of HPV-16 and p53 expression. In all, 52 or 36% of the epithelial ovarian tumours detected by ISH or IHC, respectively,
were HPV-16 E6 positive. In contrast, only 6.7% of normal ovarian tissues were HPV-16 positive proved by ISH. Human
papillomavirus-16 infection was significantly higher in cancer tissues compared to controls with an odds ratio of 16.7 (95% confidence
interval [CI]¼3.2–71.4, Po0.01). No significant correlation between HPV-16 infection and histological types of cancer was found
(P40.05). p53 gene expression was detected in 42% epithelial ovarian cancers. No correlation between p53 expression and HPV-16
infection was found. The results showed the presence of HPV-16 E6 in ovarian carcinoma, suggesting that HPV infection might play a
role in ovarian carcinogenesis.
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Human papillomavirus (HPV) infection has been identified as the
necessary cause of cervical cancer (Bosch et al, 2002). The
progression of proliferative epithelial cells at different body sites to
carcinoma may also be associated with the high-risk type HPV
infection (zur Hausen, 1999). Ovarian tumour is a common
neoplasm of the female genital tract and one of the most lethal
gynaecologic malignancies (Prazzini et al, 1997). The aetiology of
ovarian cancer remains unclear (Boyle et al, 2000). Malignancy of
epithelial origin accounts for 85–90% of the total ovarian tumour
morbidity. Therefore, the involvement of HPV infection in
epithelial ovarian cancer has been an interesting issue. However,
previous studies in different laboratories provided highly con-
troversial results (Kaufman et al, 1987; Leake et al, 1989;
Beckmann et al, 1991; Lai et al, 1992, 1994; Duggan et al, 1995;
Runnebaum et al, 1995; Sworn et al, 1995; Trottier et al, 1995;
Anwar et al, 1996; Kedzia et al, 1996; Mai et al, 1996; Zimna et al,
1997; Manolitsas et al, 1998; Anttila et al, 1999; Chen et al, 1999; Ip
et al, 2002). We report here that HPV-16 was found in a series of
histologically characterised epithelial ovarian carcinomas from
Chinese women.
The oncogenic HPV product E6 targets p53 for degradation and
therefore manipulates the host intracellular signal network in
cervical cancers (Werness et al, 1990). Less study has been
reported about p53 mutation and its relationship with HPV
infection in ovarian cancer.
MATERIALS AND METHODS
Source and histological type of specimens
The patient group consisted of 50 epithelial ovarian carcinomas
and four nonepithelial ovarian carcinomas. The mean age of the
patients was 47 years (range 27–71 years). Histological types for 50
epithelial cancers were 24 serous cystadenocarcinomas, 19
mucinous cystadenocarcinomas, five endometrioid adenocarcino-
mas, and two undifferentiated carcinomas. Histological types for
four nonepithelial cancers were two thecomas, one endodermal
sinus tumour, and one malignant mesothelioma. The control
group consisted of 30 pathologically confirmed nonmalignant
ovarian tissues collected from 30 women (mean age 53 years; range
27–62 years). Among the nonmalignant tissues, 24 were ovaries
removed for uterine pathology, five were ovarian cysts, and one
was polycystic ovarian syndrome. Specimens were paraffin-
embedded and archived from 1996–2000 in Inner Mongolia
Medical College affiliated hospital.
Sections of 5mm thickness were cut from formalin-fixed,
paraffin-embedded blocks. Tissue sections were attached on
APES-treated glass slides for in situ hybridisation (ISH) and
immunohistochemistry (IHC).
In situ hybridisation
The full-length HPV-16 E6 gene was kindly provided by Dr zur
Hausen. A 483bp E6 probe was labelled with digoxin using an
in vitro transcription kit (Boehringer Mannheim, Rocha Diagnostic
GmbH, Agency Organisation GD-M Sandhoferstr-116, D-68305
Mannheim, Germany). Briefly, the in vitro transcription vector Received 31 January 2003; revised 28 April 2003; accepted 5 June 2003
*Correspondence: Dr Y Ke; E-mail: keyang@mx.cei.gov.cn
The study was performed at Laboratory of Genetics, Beijing Institute for
Cancer Research, School of Oncology, Peking University, Beijing, China
British Journal of Cancer (2003) 89, 672–675






























ycontaining E6 gene was linearised by SalI digestion. The trans-
cription was performed with T7 RNA polymerase in the presence
of digoxin-labelled UTP and other unlabelled NTPs.
The paraffin sections were dewaxed, rehydrated and treated with
0.1 N HCl. The tissue slides were then digested with proteinase K
at 371C for 15min. The HPV-16 E6 probe was mixed with
hybridisation solution containing 50% formamide, 4 SSC, 5%
dextran sulphate, 5 Denhardt’s solution and 200mgml
 1 ssDNA.
The tissue slides were incubated overnight at 421Ci n2 0ml of the
hybridisation solution with probe. The slides were washed in SSC.
The E6 hybrid was detected by an alkaline phosphatase-conjugated
antidigoxin antibody. The tissue slides were observed under a
microscope. Pictures were taken for analyses. The HPV-16-positive
oesophageal cancer was used as positive control (Li et al, 2001).
The hybridisation solution without probes has been used as
negative control. In situ hybridisation mostly detects the
transcripts of a gene. The antisense probe hybridises with mRNA
in the test system. Therefore, sense probe is a desired negative
control. However, E6 integration in the host genome might result
in transcription in both directions (Higgins et al, 1991; Vormwald-
Dogan et al, 1992). Therefore, blank hybridisation was used as the
control in this report.
Immunohistochemistry
Specimens were dewaxed and treated with PBS containing 3%
hydrogen dioxide. Slides were incubated at 37
0C in normal goat
serum for 15min to eliminate nonspecific binding. Samples were
incubated with either anti-HPV-16 E6 antibody (Santa Cruz
Biotechnology, 2145 Delaware Ave., Santa Cruz, CA 95060, USA,
1:100 dilution) or anti-p53 antibody (Santa Cruz Biotechnology,
1:100 dilution) at 41C overnight. The biotinylated secondary
antibody and HRP-labelled streptavidin were then added and
incubated at 371C for 30min. The signal was developed in DAB–
H2O2 solution. The slides were counterstained with haemotoxylin.
Statistical analysis
Statistical analysis was performed using w
2 test and odds ratio was
used to determine prevalence of HPV-16 infection in epithelial
ovarian cancers, nonepithelial ovarian cancers, and normal
ovarian tissues.
RESULTS
In 50 epithelial ovarian cancers, 26 were HPV-16 E6 positive
determined by ISH. The positive rate is 52%. Only two or 6.7% of
the normal ovarian tissue samples showed HPV-16 positive using
ISH (Table 1, Po0.01 OR¼16.7 95% CI B3.2–71.4). Human
papillomavirus-16 E6 was not detected in any of the nonepithelial
ovarian cancers (Table 2). The purple signals represent HPV-16 E6
located mainly in the cytoplasm as described (Vormwald-Dogan
et al, 1992) (Figure 1).
Using immunohistochemical stain, 18 or 36% of the epithelial
ovarian cancers were HPV-16 positive. All the positive samples
detected by IHC were those positive samples detected by ISH. The
brown signal located in the cytoplasm represents E6 protein (Figure 2).
A total of 21 or 42% of the epithelial ovarian cancers were p53
positive. The brown signal located uniquely within the nucleus
represents p53 protein. No correlation has been found between
HPV-16 infection and p53 positive (Table 3, P40.05).
HPV-16 infection was not identified in any nonepithelial ovarian
cancers, which are not the primary host for HPV. There was no
correlation between HPV infection and histological types of
Table 1 HPV-16 E6 detection in epithelial ovarian carcinomas and
normal ovaries by ISH
Tested case Positive Percentage
Ovarian carcinoma 50 26 52
Normal ovary 30 2 6.7
Po0.01; w
2 test; OR¼I6.7, 95% CI (3.2–71.4).
Table 2 HPV-16 E6 detection in different histological types of ovarian
carcinoma
ISH IHC
Histological types Nn % n %
Serous cystadenocarcinoma 24 15 62.5a 10 41.7
b
Mucinous cystadenocarcinoma 19 8 47.4 5 26.3
Endometrioid adenocarcinoma 5 2 2












Figure 1 HPV-16 E6 in ovarian cancers by ISH, (A) sample no. 990917
and (B) sample no. 990193. The purple blue signals representing the
expression of the E6 mRNA are at cytoplasm in the tumour cells. (A, B:
original magnification 100).
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yovarian cancers (Table 2, P40.05). Owing to the sample size
limitation, statistical comparison was only carried out between
cystadenocarcinomas and mucinous cystadenocarcinomas.
DISCUSSION
Human papillomaviruses play a causal role in cervical cancer.
Human papillomavirus infection is also detected in other
cancers of the female lower genital tract, including cancers of
vulva, vagina, and perineum (Gupta et al, 1987; Shah et al,
1996; Dillner et al, 1997). However, the role of HPV infection in
the development of cancers in the upper genital tract, such as
endometrial cancer and ovarian cancer, is less clear. The first
report on HPV infection in ovarian cancers was published in 1987
(Kaufman et al, 1987), although the article was retacted 1 year later
by the authors. To date about 16 additional reports on HPV
infection in ovarian tumours were found in the MEDLINE. Among
these, 10 analysed more than 10 tumour specimens in each report
(Leake et al, 1989; Beckmann et al, 1991; Lai et al, 1992, 1994;
Runnebaum et al, 1995; Trottier et al, 1995; Zimna et al, 1997;
Anttila et al, 1999; Chen et al, 1999; Ip et al, 2002). Only in four of
the 10 studies, HPV infection was found in ovarian cancers (Lai
et al, 1992, 1994; Zimna et al, 1997; Ip et al, 2002). It is interesting
that in three of the positive reports, specimens of Chinese origin
were used (Lai et al, 1992, 1994; Ip et al, 2002). In the present
study, a total of 54 ovarian cancers and 30 nontumour ovarian
specimens were analysed for the presence of HPV-16. Among the
50 epithelial ovarian cancers, a total of 26 (52%) HPV-16 positive
were found. Our results are consistent with those reports based on
Chinese origin specimens. These independent studies are from
three areas of grand China, Mainland China, Taiwan, and Hong
Kong, suggesting that host genetic makeup may play an important
role in susceptibility to HPV infection. Alternatively, HPV
intratypic variants in different geographical regions may also
determine the association with the risk of ovarian cancer. It has
been reported that the distribution of HPV variants varied in
different geographical areas, suggesting that the virus and the
host have coevolved over time (Ho et al, 1993; Ong et al, 1993;
Heinzel et al, 1995; Stewart et al, 1996; Yamada et al, 1995, 1997;
Hildesheim et al, 2002). Epidemiology studies in cervical cancers
showed that individuals infected with a non-European variant of
HPV-16 were associated with 2–9- fold increased risk of cervical
cancer (Hildesheim et al, 2002). Whether this is the case in ovarian
cancer needs to be further investigated.
In addition to the host and pathogen genetic variation, the
difference of the detection methods employed in the studies might
also account for data discrepancy. It has been well documented in
cervical cancer that the episomal viral DNA frequently integrates
into the host genome as HPV-infected lesions progress to cervical
cancer. During viral DNA integration, only E6 and E7 genes
remained (zur Hausen, 2002) in the host genome. Therefore, the
presence of E6 or E7 genes in tumour tissues may better represent
the real HPV infection. In some studies, L1 was used as the only
indicator, which may have been lost or not expressed in the
malignant specimens. We suggest that a well recognised standard
for HPV detection in tumours should be issued for further studies.
In this study, we employed both ISH and IHC to detect HPV-16
E6 expression. Among the 26 HPV-16-positive cancer samples
detected by ISH, 18 were confirmed positive by IHC. More import-
antly, none of ISH-negative samples were detected positive by IHC.
These results indicate that IHC is an accurate method with less
sensitivity.
The prevalence of HPV-16 infection in ovarian cancers is much
higher than in nonmalignant ovarian tissues, suggesting that HVP-
16 infection may play a role in the development of ovarian cancer.
However, large case–control studies need to be conducted before
reaching a conclusion.
Mutations of p53 are frequently detected in ovarian cancer
(Crook et al, 1992; Kmet et al, 2003). Consistent with those studies,
we found that 42% of ovarian cancers were p53 positive. The
expression of p53 was not correlated with HPV infection. It has
been proposed that the mechanism for the loss of p53 function in
cervical cancer is due to degradation by HPV E6. Therefore, p53
mutation is rare in cervical cancers. However, there are reports
suggesting that the association between HPV infection and p53
mutation differs among tumours (Hachisuga et al, 1996; Hasegawa
et al, 2002), suggesting that additional mechanisms may be
involved in tumorigenesis of other origins.
Figure 2 HPV-16 E6 in ovarian cancers by IHC, (A) sample No. 990917
and (B) sample no. 990589. The brown signals representing the expression
of the E6 protein are mainly at cytoplasm in the tumour cells. (A, B: original
magnification  100).
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